Scientists combat antibiotic-resistant bacteria using combination therapies and novel bacteriophages.
the verdict
SUPPORTED
the evidence backs this
refutedsupported
the weight of evidence
5 sources for · 0 against
Peer-reviewed literature documents that scientists are actively combating antibiotic-resistant bacteria using combination therapies, such as phage-antibiotic synergy, and novel bacteriophage applications.
Antibiotics have revolutionized medicine, saving countless lives since their discovery in the early 20th century. However, the origin of antibiotics is now overshadowed by the alarming rise in antibiotic resistance. This global crisis stems from the relentless adaptability of microorganisms, driven by misuse and overuse of antibiotics. This article explores the origin of antibiotics and the subsequent emergence of antibiotic resistance. It delves into the mechanisms employed by bacteria to develop resistance, highlighting the dire consequences of drug resistance, including compromised patient care, increased mortality rates, and escalating healthcare costs. The article elucidates the latest strategies against drug-resistant microorganisms, encompassing innovative approaches such as phage therapy, CRISPR-Cas9 technology, and the exploration of natural compounds. Moreover, it examines the profound impact of antibiotic resistance on drug development, rendering the pursuit of new antibiotics economically challenging. The limitations and challenges in developing novel antibiotics are discussed, along with hurdles in the regulatory process that hinder progress in this critical field. Proposals for modifying the regulatory process to facilitate antibiotic development are presented. The withdrawal of major pharmaceutical firms from antibiotic research is examined, along with potential strategies to re-engage their interest. The article also outlines initiatives to overcome economic challenges and incentivize antibiotic development, emphasizing international collaborations and partnerships. Finally, the article sheds light on government-led initiatives against antibiotic resistance, with a specific focus on the Middle East. It discusses the proactive measures taken by governments in the region, such as Saudi Arabia and the United Arab Emirates, to combat this global threat. In the face of antibiotic resistance, a multifaceted approach is imperative. This article provides valuable insights into the complex landscape of antibiotic development, regulatory challenges, and collaborative efforts required to ensure a future where antibiotics remain effective tools in safeguarding public health.
Background: Antimicrobial resistance (AMR) is a major global health challenge requiring innovative therapeutic strategies. Phage–antibiotic combination therapy has emerged as a potential approach for treating multidrug-resistant (MDR) bacterial infections. This systematic review summarizes reported synergistic effects and clinical outcomes of this combined strategy. Methods: This review was conducted according to PRISMA guidelines. PubMed, Scopus, Web of Science, and the Cochrane Library were searched for studies published between January 2000 and December 2024 assessing combined bacteriophage and antibiotic therapy against MDR bacteria. Eligible studies focused on therapeutic synergy, bacterial resensitization, and clinical outcomes, with results synthesized narratively. Results: A total of 25 studies were included, comprising 10 in vitro studies, 7 in vivo animal studies, and 8 clinical investigations. Phage–antibiotic combinations demonstrated synergistic effects in more than 70% of cases, resulting in enhanced bacterial eradication, improved biofilm disruption, and reduced resistance development compared with monotherapy. The mean Fractional Inhibitory Concentration Index (FIC-I) for synergistic combinations in in vitro studies was 0.29±0.11. Animal studies reported protection or survival rates ranging from 64% to 100%. Clinical reports, including case studies and one phase 2 trial, documented successful treatment of refractory MDR infections without major safety concerns, although adverse events were inconsistently reported. Conclusion: Phage–antibiotic combination therapy appears to be a promising approach for managing MDR bacterial infections. Despite encouraging evidence of enhanced efficacy, challenges such as phage resistance, host immune responses, and variability in interactions remain. Larger, well-designed clinical trials and individualized testing are necessary to confirm clinical efficacy and optimize therapeutic application.
<h4>Objectives</h4>To evaluate the comparative efficacy and safety of colistin monotherapy, colistin-based combination regimens, and alternative antibiotic strategies within a unified analytical framework for multidrug-resistant (MDR) Gram-negative infections.<h4>Methods</h4>Systematic search of PubMed, the Cochrane Library, Embase, and Web of Science was conducted from inception to July 15, 2025. A network meta-analysis integrating direct and indirect evidence was performed to estimate risk ratios (RRs) with 95% confidence intervals (CIs).<h4>Results</h4>A total of 17 randomized controlled trials with 1760 patients were included. Beta-lactam (BL) therapy combined with a beta-lactamase inhibitor (BLI) was associated with a significant reduction in all-cause mortality compared with colistin monotherapy (RR 0.62, 95% CI 0.39-0.99; very low certainty evidence). Colistin-based combination therapies, particularly combinations of colistin with BL/BLIs, achieved higher clinical cure (RR 4.43, 95% CI 1.44-13.66; very low certainty evidence) and microbiological eradication rates (RR 9.50, 95% CI 1.34-67.27; very low certainty evidence) than colistin monotherapy. In terms of safety, BL/BLI-based regimens were associated with significantly lower risks of nephrotoxicity compared with colistin-based regimens.<h4>Conclusion</h4>Beta-lactam therapy combined with a beta-lactamase inhibitor was associated with a significant reduction in all-cause mortality while colistin-based combination therapies particularly combinations of colistin with beta-lactam/beta-lactamase inhibitors were associated with improved clinical and microbiological outcomes compared with colistin monotherapy. However, the low to very low certainty evidence across most comparison-preclude a firm conclusion on the effects of colistin or other antibiotic therapy for MDR Gram-negative infections. Well-designed randomized controlled trials directly comparing colistin-based combinations with newer BL/BLI therapies are needed to better define the optimal treatment strategy for MDR Gram-negative infections.
<h4>Objectives</h4>The interest in bacteriophage therapy has significantly increased due to the rising prevalence of antibiotic-resistant bacterial infections. However, the pharmacology of bacteriophage therapy has not been systematically reviewed. This scoping review aims to summarize the current state of bacteriophage pharmacokinetics and pharmacodynamics research to identify knowledge gaps and guide future research.<h4>Methods</h4>Following PRISMA-ScR guidelines, we conducted a scoping review through December 18th, 2023 of MEDLINE (Ovid), PubMed, Embase (Elsevier), Web of Science Core Collection (Clarivate), and Cochrane Central. We included studies that presented original data on the pharmacokinetics and pharmacodynamics of bacteriophage therapy for in vivo infection treatment.<h4>Results</h4>In total, 34 in vivo studies were identified varying in multiple dimensions, including model organisms, target bacteria, delivery vehicles, modes of administration, and phage type. The scoping review maps the current research landscape of in vivo bacteriophage pharmacology.<h4>Conclusions</h4>Bacteriophage therapy shows notable promise as a potential alternative or therapeutic adjunct to antibiotics in clinical disease settings. Several studies of phage pharmacokinetics and pharmacodynamics have been conducted; however, these studies differ in multiple dimensions, complicating attempts to develop general principles for standardized phage administration. Further, significant gaps remain in understanding the numerous intrinsic phage and host factors that might affect the pharmacokinetics and pharmacodynamics of phage therapy in vivo.
Antimicrobial resistance (AMR) remains one of the most serious global threats to public health, driven by the rapid emergence and dissemination of multidrug-resistant bacterial pathogens that compromise existing antibiotic therapies. In response, the World Health Organization (WHO) has defined priority lists of antibiotic-resistant bacteria to guide research, innovation, and drug development efforts. This narrative review synthesizes current knowledge on the molecular mechanisms underlying resistance in WHO-priority pathogens, including reduced membrane permeability, efflux pump overexpression, enzymatic drug inactivation, target modification, biofilm formation, and horizontal gene transfer. Beyond mechanistic insights, we critically evaluate the therapeutic limitations of conventional antibiotics, the failure of traditional discovery pipelines, and the growing clinical and economic burden of resistant infections. Emerging strategies, including artificial intelligence-assisted drug discovery, phage therapy, antimicrobial peptides, CRISPR-based systems, resistance-modifying combinations, and natural product-derived compounds and plant compounds, are assessed with emphasis on pharmacological feasibility, translational challenges, and clinical relevance. Particular attention is given to issues of delivery, toxicity, dosing optimization, resistance emergence, regulatory barriers, and real-world implementation. Finally, we highlight the central role of antimicrobial stewardship, surveillance, and a One Health framework integrating human, animal, and environmental sectors in mitigating resistance and sustaining therapeutic effectiveness. Collectively, this review underscores that addressing WHO-priority pathogens will require integrated, multidisciplinary strategies that bridge molecular biology, pharmacology, clinical translation, and public health.
Everything we examined (5)
This check searched the claim as stated. It did not run a separate search for evidence against it.